Repository logo
 
Publication

Safety profile of gestrinone: a systematic review

2025-05Journal article Open access
Simple item page
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorFagundes, Vitor Luís
dc.contributor.authorMarques, Nathália Barreiro
dc.contributor.authorLima, Amanda Franco de
dc.contributor.authorCobre, Alexandre de Fátima
dc.contributor.authorTonin, Fernanda
dc.contributor.authorLazo, Raul Luna
dc.contributor.authorPontarolo, Roberto
dc.date.accessioned2025-06-04T14:26:34Z
dc.date.available2025-06-04T14:26:34Z
dc.date.issued2025-05
dc.descriptionThe authors express their gratitude to the Brazilian National Council of Technological and Scientific Development (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)-Finance Code 001.
dc.description.abstractBackground: Gestrinone is a synthetic hormone derived from 19-nortestosterone, exhibiting androgenic, anabolic, anti-progestogenic, and antiestrogenic effects. Gestrinone subcutaneous implants have been used “off label” for aesthetic purposes due to their anabolic action, promoting accelerated metabolism and muscle gain. Objective: Our goal is to conduct a systematic review focused exclusively on identifying the safety profile of gestrinone use, without addressing efficacy. Methods: This systematic review was performed according to the Joanna Briggs Institute and Cochrane Collaboration recommendations and is reported following the Preferred Reporting Items for Systematic Reviews and Network Meta-Analyses. This article’s searches were carried out in the PubMed, Embase, and Web of Science databases. Results: A total of 32 articles were included in this study. The reported adverse events associated with the use of gestrinone were amenorrhea (41.4% of cases), acne, seborrhea (42.7% of reports), decreased libido (26.5%), and hot flushes (24.2%). Other nonspecific symptoms, such as hoarseness and cramps, were also fairly reported (3.5% and 18.6%, respectively). Other reported effects were associated with breast size reduction (23.7% of patients) and increased transaminases (15.1%). Most studies (40%, n = 24 studies) found significant weight gain (ranging from 0.9 to 8 kg per patient). Abnormalities in bone mineral density were reported in four studies. Conclusions: The evidence remains insufficient to fully understand the risks of gestrinone use associated with its widespread, unregulated use. Thus, further standardized studies and regulatory oversight to ensure patient safety are needed to mitigate potential health risks.eng
dc.identifier.citationFagundes VL, Marques NC, Lima AF, Cobre AF, Tonin FS, Lazo RE, et al. Safety profile of gestrinone: a systematic review. Pharmaceutics. 2025;17(5):638.
dc.identifier.doi10.3390/pharmaceutics17050638
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10400.21/21903
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI AG
dc.relation.hasversionhttps://www.mdpi.com/1999-4923/17/5/638
dc.relation.ispartofPharmaceutics
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAdverse effects
dc.subjectAnabolic action
dc.subjectGestrinone
dc.subjectHormonal implants
dc.subjectSynthetic hormones
dc.titleSafety profile of gestrinone: a systematic revieweng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue5
oaire.citation.startPage638
oaire.citation.titlePharmaceutics
oaire.citation.volume17
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameTonin
person.givenNameFernanda
person.identifier.ciencia-idD01C-C700-9411
person.identifier.orcid0000-0003-4262-8608
person.identifier.ridO-2050-2017
person.identifier.scopus-author-id56085115800
relation.isAuthorOfPublication61ded30e-ecec-4b3e-b953-2293e080ebdd
relation.isAuthorOfPublication.latestForDiscovery61ded30e-ecec-4b3e-b953-2293e080ebdd

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Safety profile of gestrinone_a systematic review.pdf
Size:
3.93 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos